United States · Who invested in Advent Therapeutics?
Advent Therapeutics's investors include Ben Franklin Technology Partners, National Institutes of Health and Ben Franklin Technology Partners of Southeastern Pennsylvania.
2016201820202022
$50KSeed$3.0MGrantUnited States · Funded startup
Who invested in Advent Therapeutics
Funding summaryUpdated 26 Oct 2026
$3.0Mraised across 2 rounds since 2014, from 2 sources
$50KSeed$3.0MGrant
- Latest round
- Grant, $3.0MJul 2023
- Step-upi
- 60×
- Investors
- 3
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Seed, $50K Aug 2014
- Biggest round
- $3.0M Grant · Jul 2023
- Between rounds
- 8.8 years from the last two
The rounds
- Jul 2023Grant$3.0M2 new1 returning
National Institutes of Health
Ben Franklin Technology Partners
Ben Franklin Technology Partners of Southeastern Pennsylvania
Source recorded
- Aug 2014
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Advent Therapeutics
How much has Advent Therapeutics raised?
Advent Therapeutics has raised $3.0M across 2 rounds since 2014.
When did Advent Therapeutics last raise?
Advent Therapeutics's most recent round was a Grant of $3.0M in Jul 2023.
What was Advent Therapeutics's biggest round?
Its most recent round, $3.0M in Jul 2023, is also its largest on record.
Who backed Advent Therapeutics first?
Advent Therapeutics's first round on record, in Aug 2014, was backed by Ben Franklin Technology Partners.
What stage is Advent Therapeutics at?
Advent Therapeutics's latest named round is a Grant, in Jul 2023.
Where is Advent Therapeutics based?
Advent Therapeutics is based in the United States.
Companies like Advent Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.